Reply to: A Phase 2 Randomised Controlled Trial of Nicotinamide for Skin Cancer Chemoprevention in Renal Transplant Recipients

Abstract

We have read with interest the paper by Chen et al. in which oral nicotinamide is used to prevent keratinocyte carcinomas (KC; basal and squamous cell carcinomas of the skin) in renal transplant patients.¹ The current study suggests nicotinamide is safe and effective to prevent the development of KC in this high-risk group, similarly to a study by the same group in non-transplant patients (ONTRAC study, Oral Nicotinamide To Reduce Actinic Cancer).

This article is protected by copyright. All rights reserved.

http://ift.tt/2foT4Ih